INFED PRESCRIBING INFORMATION PDF

INFED PRESCRIBING INFORMATION PDF

INFeD® improved the hemoglobin response to erythropoietic therapy in patients with documented INFeD® full Prescribing Information. Watson Pharma, Inc. 1 mL of INFeD provides 50 mg of elemental iron UpToDate (courtesy of Lexicomp), or the prescribing information. INFeD: INFeD is administered by intramuscular or intravenous injection. Before . during the acute phase of infectious renal disease (manufacturer’s information) . Therefore, the therapeutic prescription use of iron is usually compatible with.

Author: JoJojind Tokora
Country: Antigua & Barbuda
Language: English (Spanish)
Genre: Health and Food
Published (Last): 26 May 2018
Pages: 319
PDF File Size: 1.57 Mb
ePub File Size: 4.72 Mb
ISBN: 264-5-26481-580-8
Downloads: 90276
Price: Free* [*Free Regsitration Required]
Uploader: Gojar

Iron stores are utilized in erythropoiesis and can be depleted during therapy even in patients with normal pre-treatment iron concentrations. DO NOT mix iron dextran with other medications. Recipient’s Email Separate multiple email address with a comma Please enter valid email address Recipient’s email is required. Total Dose Intravenous Ibformation []: Patients with hemoglobinopathy and other refractory anemias that might be erroneously diagnosed as iron deficiency anemias are at particular risk for such iron overload.

See individual dosage if using total dose IV infusion methods.

It would be illogical for a patient to receive both iron supplementation and deferasirox simultaneously. Your email has been sent.

Because anaphylactic reactions are known to occur after uneventful test doses, test doses before subsequent doses should be considered. Since the anemia may be a result of a systemic disturbance, such as recurrent blood loss, the underlying cause s should be corrected, if possible. Send the page ” ” to a friend, relative, colleague or yourself. Parenteral administration of iron dextran may exacerbate joint pain and swelling in patients with rheumatoid arthritis, ankylosing spondylitis, or systemic lupus erythematosus SLE.

Minor Iron stores should be replete before and during treatment with an ESA.

Iron dextran (INFeD) | – A Hematology Oncology Wiki

Instructions for test dose administration for all indications. Once the infusion is completed, flush vein with NS injection. Visually inspect parenteral products for particulate matter and discoloration prior to administration whenever solution and container permit. There are no adequate and well-controlled studies in pregnant women. Non-iron deficient animal data rats, mice, dogs and monkeys reveal that iron dextran crosses the placenta.

  CADA SET ONADES PDF

Do not add therapeutic doses of iron dextran to total parenteral nutrition TPN solutions; iron dextran may destabilize the mixture or cause the cracking of the TPN emulsion. Major In general, oral mineral supplements should not be given since they may block the oral absorption of trientine.

Iron dextran (INFeD)

While the manufacturer recommends 25 mg 0. Since deferiprone has the potential to bind polyvalent cations e. Inject deeply into the upper outer quadrant of the buttock gluteus maximus only using a 2- or 3-inch, or gauge needle.

Transferrin eventually becomes available for reuse. Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk of an untreated or inadequately treated condition.

Furthermore, concomitant use of angiotensin-converting enzyme inhibitors may increase the risk for serious reactions to iron dextran. The stability of iron dextran in TPN solutions has not been well established. Parenteral iron supplement of ferric oxyhydroxide complexed with dextrans; rapidly repletes iron stores in deficiency from anemia or blood loss; sometimes associated with severe hypersensitivity. Specific guidelines for dosage adjustments in hepatic impairment are not available.

If test dose uneventful, doses of 1. Because anaphylactic reactions are known to occur after uneventful test doses, subsequent test doses should be considered. Inject via slow IV at a gradual rate not to exceed 50 mg 1 mL per minute for adults; take care to inject dosage very slowly in children and infants. Monitor patients for signs and symptoms of anaphylactoid reactions during all iron dextran administrations. Cardiac disease, hypotension, intravenous administration. Deferoxamine is indicated as a treatment of iron toxicity or overdose.

The factors that affect the risk for anaphylactic-type reactions to iron dextran products are not fully known but limited clinical data suggest the risk may be increased among patients with a history of drug allergy or multiple drug allergies. Observe the patient for at least 1 hour after test dose administration. Achieving and maintaining adequate iron stores are essential to attaining an optimal response to MPG-epoetin beta.

  EL PEREGRINO JUAN BUNYAN PDF

The following are generally accepted limits in the treatment of iron-deficient patients. Patients with a significant history of allergies e. If test dose uneventful, give the remainder of the total dose as mg of elemental iron per day IM or slow IV until the total calculated dose is given.

If test dose uneventful, give the remainder of the total informatikn as mg elemental iron per day IM or IV until the total calculated dose is given. Moderate The concomitant use of angiotensin-converting enzyme inhibitors ACE inhibitors with iron dextran may increase the risk for anaphylactic-type reactions.

PDR Search

Patients who require parenteral nutrition for a limited period of time and who are not iron-deficient do not need parenteral iron supplementation. Do not administer iron dextran to patients with evidence of iron overload e. Iron dextran is classified in FDA pregnancy risk category C. In general, do not administer parenteral iron concomitantly with other iron preparations e.

Ferric iron is then gradually released into the plasma where it combines rapidly with transferrin. Adults, Adolescents, Children, and Infants 4 months and older. Therapeutically, it is typically illogical for a patient to receive both iron supplementation e. Give DexFerrum test doses gradually over at least 5 minutes. Iron dextran is contraindicated in patients with iron dextran hypersensitivity.

Before administering therapeutic doses by any route, a test dose of of iron dextran should be given by the route and method of administration for which therapeutic doses are innformation be administered.